Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Status:
Recruiting
Trial end date:
2028-11-15
Target enrollment:
Participant gender:
Summary
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute
Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD)
after KTE-X19 CAR T-cell therapy
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute